Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results

Eye (Basingstoke)

Volumn 28, Issue 7, 2014, Pages 895-899

  Grewal, D S ^a   Gill, M K ^a   Sarezky, D ^a   Lyon, A T ^a   Mirza, R G ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL FOVEAL THICKNESS; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; CYST FLUID; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; MACULAR VOLUME; MALE; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL FLUID; TREATMENT DURATION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

EID: 84922020078     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.101     Document Type: Article

References (10)

1. Group CR, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-1908.
2. Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina 2012; 32: 434-457.
3. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE et al. Short-Term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 2013; 156(1): 23-28.e2.
4. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 2013; 156: 15-22. e11.
5. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JT, Sobrin L, Eliott D et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 2013; 156(1): 29-35.e2.
6. Cho H, Shah CP, Weber M, Heier JS. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 2013; 97: 1032-1035.
7. Patel KH, Chow CC, Rathod R, Mieler WF, Lim JI, Ulanski 2nd, LJ et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond) 2013; 27: 663-668.
8. Kumar N, Marsiglia M, Mrejen S, Fung A. T, Slakter J, Sorenson J et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 2013; 33: 1605-1612.
9. Chaikitmongkol V, Bressler NM. Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use. JAMA Ophthalmol 2013; 131: 260-262.
10. Ehlers JP, Spirn MJ, Shah CP, Fenton GL, Baker PS, Regillo CD et al. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors. Ophthalmic Surg Lasers Imaging 2010; 41: 182-189.